Axovant Sciences Ltd.

General Information
Business:

We are a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Our goal is to be the leading biopharmaceutical company focused on the treatment of dementia, a condition characterized by a significant decline in mental capacity and impaired daily function. Our near-term focus is to develop our product candidate, which we refer to as RVT-101, for the treatment of Alzheimer’s disease and other forms of dementia. In the long-term, we intend to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 7
Founded: 2014
Contact Information
Address Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda
Phone Number +1 (441) 295 5950
Web Address http://www.axovant.com
View Prospectus: Axovant Sciences Ltd.
Financial Information
Market Cap $1440.0mil
Revenues $0.0 mil (last 12 months)
Net Income $-21.0 mil (last 12 months)
IPO Profile
Symbol AXON
Exchange NYSE
Shares (millions): 21.0
Price range $15.00 - $15.00
Est. $ Volume $315.0 mil
Manager / Joint Managers Jefferies/ Evercore ISI/ RBC Capital Markets
CO-Managers JMP Securities/ Baird
Expected To Trade: 6/11/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change